Victory Capital Management Inc. Acquires 111,915 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Victory Capital Management Inc. lifted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 112.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 211,130 shares of the company's stock after purchasing an additional 111,915 shares during the period. Victory Capital Management Inc. owned about 0.07% of Amneal Pharmaceuticals worth $1,672,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $81,000. Quest Partners LLC bought a new stake in shares of Amneal Pharmaceuticals during the third quarter worth about $84,000. Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $121,000. Quadrature Capital Ltd bought a new stake in shares of Amneal Pharmaceuticals during the third quarter worth about $169,000. Finally, Entropy Technologies LP bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $259,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Down 3.9 %

AMRX traded down $0.35 during trading on Friday, hitting $8.66. The company's stock had a trading volume of 2,177,319 shares, compared to its average volume of 1,352,236. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.18 and a twelve month high of $9.48. The stock's fifty day moving average price is $8.38 and its 200-day moving average price is $8.37. The firm has a market capitalization of $2.68 billion, a P/E ratio of -12.74 and a beta of 1.05.

Remove Ads

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same period last year, the firm posted $0.14 earnings per share. Equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 17,410 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company's stock, valued at $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,240,000 shares of company stock valued at $43,754,000. 26.56% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Barclays upped their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Finally, StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $10.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.